Genetics study to find why HER2 breast cancer treatment varies
Part of Cancer clinical trials.
This study looks at genetic factors to understand why some people’s HER2-positive breast cancer responds better—or has more side effects—after treatment. Your info and possible past treatment history may help researchers improve how HER2 treatment is chosen and managed.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 18 or older.
- You have breast cancer confirmed by pathology (breast adenocarcinoma), and it is not metastatic (not spread).
- Your breast cancer is considered operable (can be treated with surgery).
- You have had (now or before) treatment that targets HER2 as part of adjuvant or neoadjuvant care (before or after surgery).
- You can and are willing to sign written informed consent and follow the study visits/tests.
- You should be able to complete study assessments without major geographic, social, or psychological barriers.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a personalized treatment approach for HER2-positive breast cancer. It uses regular monitoring of your tumor to adjust the treatment before surgery, aiming to improve results. It might help you by tailoring therapy to your cancer's response.
This study tests different treatments tailored to your cancer's biology. It aims to find which therapy might work best for you, potentially improving outcomes. You'd receive one of the study drugs, with close monitoring and support.
This study looks at the genetic details of HER2-positive breast cancer to help find subtypes and improve future treatments. It does not test a new drug but collects information from your tumor tissue to learn more about the disease.
This study looks at how well a new test can help manage her2-positive early-stage breast cancer. It includes patients who have had treatment before or after surgery with trastuzumab and possibly pertuzumab.
This study looks at how your immune system reacts to anti-HER2 treatments in people with HER2-positive breast cancer. It may help doctors understand who responds best by studying immune signals in blood (and sometimes tissue) during or after treatment.
This trial studies breast cancer tumors to see how specific gene changes and DNA damage patterns relate to the cancer in people with HER2-low disease. It may help doctors better predict which patients could benefit from treatments that target these pathways.
Hear when a new HER2-positive Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.